Table 2.

Study purpose, risk factors, registries, and funding, 31 SEER biospecimen studies, 2005 to 2013

AttributeNReferences
Study purpose
 Etiology19(10–15, 17, 19, 20, 24, 26–29, 31, 33, 34, 37, 38)
 Prognosis8(8, 11, 14, 21–23, 35, 36)
 Detection, development, and progression6(16, 18, 24, 33, 37, 38)
Risk factors
 HPV6(14, 15, 17, 20, 31, 34)
 Tobacco3(10, 29, 31)
 Viral hepatitis2(19, 33)
 Agricultural chemical exposure2(12, 13)
 Other (one each)a8(10, 24, 26, 27, 28, 33, 37, 38)
Registries
 Hawaii20(8, 9, 14, 15, 17, 22, 24–27, 32–37)
 Iowa19(8, 10–17, 20, 21, 23, 25, 26, 29, 30, 34–36)
 Los Angeles15(8, 11, 13, 14, 17, 20, 21, 25, 26, 34–36, 38)
 Detroit, Kentucky, Seattle, Louisiana5(11, 13, 17, 20, 31)
 SEER/NPCR collaboration3(17, 20, 34)
Funding
 SEER contract30(8–30, 32–38)
 NCI intramural program10(9, 10, 12–14, 19, 25, 26, 28, 36)
 CDC NPCR3(17, 20, 34)
 Otherb3(15, 16, 28–31)
  • aRadon (10), soy intake (24), Epstein-Barr virus infection (26), parity (27), HIV infection (28), alcohol use (33), mammographic tissue density (37), and menopausal hormone therapy (38).

  • bInternational Public and Private Consortium (15), NCI Office of HIV & AIDS Associated Malignancies (28), RO1 grant from NCI (16, 29, 30), and NCI Rapid Response Surveillance Studies (31).